

**Evidence Review Committee Member Relationships With Industry and Other Entities (Comprehensive)—Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (May 2017)**

<b>Committee Member</b>	<b>Employment</b>	<b>Consultant</b>	<b>Speakers Bureau</b>	<b>Ownership/ Partnership/ Principal</b>	<b>Personal Research</b>	<b>Institutional, Organizational, or Other Financial Benefit</b>	<b>Expert Witness</b>
Peter W. F. Wilson (Chair)	Emory Clinical Cardiovascular Research Institute—Professor of Medicine	<ul style="list-style-type: none"> <li>• DCRI 1 (NIH)</li> <li>• DCRI (Eric Peterson)†</li> </ul>	None	None	None	None	None
Tamar S. Polonsky (Vice Chair)	The University of Chicago—Assistant Professor of Medicine	None	None	None	None	<ul style="list-style-type: none"> <li>• AstraZeneca‡</li> </ul>	None
Amit Khera	The University of Texas Southwestern Medical Center—Professor of Medicine	None	None	None	None	None	None
Andrzej S. Kosinski	Duke University—Associate Professor of Biostatistics	None	None	None	<ul style="list-style-type: none"> <li>• AHA</li> <li>• AHRQ*</li> <li>• Duke Preseton Robert Tisch Brain Tumor Center (DSMB)</li> <li>• NIH*</li> <li>• PCORI*</li> <li>• Society of Thoracic Surgeons*</li> <li>• The Marcus Foundation*</li> </ul>	None	None
Jeffrey T. Kuvin	Dartmouth-Hitchcock Medical Center—Professor of Medicine	None	None	None	None	None	None
Michael D. Miedema	Minneapolis Heart Institute—Research Cardiologist	None	None	None	None	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥\$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer

to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

\*Significant relationship.

†No financial benefit.

‡On March 1, 2018 after writing of this Systematic Review was complete with the exception of ODYSSEY OUTCOMES inclusion, Dr. Polonsky, after having reviewed her listing on the CMS Open Payments Data website, realized that she had been a local PI in the STRENGTH trial, supported by AstraZeneca, and promptly reported this to the Task Force. Only 1 patient was recruited, and Dr. Polonsky did not receive any direct salary support, but by ACC/AHA standards, this would constitute a relationship with industry (RWI) and thus, in the interest of full transparency, this footnote has been added.

AHA indicates American Heart Association; AHRQ, Agency for Healthcare Research and Quality; DCRI, Duke Clinical Research Institutes; DSMB, Data Safety Monitoring Board; NIH, National Institutes of Health; PCORI, Patient-Centered Outcomes Research Institute.